To buy shares in BioCryst Pharmaceuticals Inc. you will need a US based stock trading platform like Interactive Brokers or Moomoo where it currently costs $9.7 to buy one share in BioCryst Pharmaceuticals Inc. (as of 16:00 18-Aug-2026). Which is a change of $0.24 or -2.41% from the last closing price of $9.94.
How To Buy BioCryst Pharmaceuticals Inc. Stock
It may seem complicated to buy stock for the first time, but it’s actually very easy. Follow these simple steps to buy shares in BioCryst Pharmaceuticals Inc.:
- Pick a stock broker (jump down to compare the best brokers for buying BioCryst Pharmaceuticals Inc. stock)
- Deposit funds (bank transfer, ACH, wire transfer, or card)
- Search for the stock symbol: (NASDAQ:BCRX)
- Choose the number of shares you want to buy (1 share currently costs $9.7)
- Click buy (you can either trade immediately at “market” or set a “limit” to buy the stock cheaper if you think the price will go down)
- Track the performance of your BioCryst Pharmaceuticals Inc. stock in your account (this will show your profit and loss)
[qmod detailedquotetabchart BCRX:US name=”BioCryst Pharmaceuticals Inc.” show_profile=”1″ ticker=”BCRX” heading=”h2″]
- BioCryst Pharmaceuticals Inc. is currently worth $2,478,690,421 based on the last closing price of $9.94 with 0 shares traded.
- The most recent BioCryst Pharmaceuticals Inc. daily high has been $9.94 and daily low $9.55.
- The BioCryst Pharmaceuticals Inc. stock price 52 week high has been $11.22 and the 52 week low $6.
Compare Brokers For Buying BioCryst Pharmaceuticals Inc. Stock
Is Now A Good Time To Buy BioCryst Pharmaceuticals Inc. Stock?
- BioCryst Pharmaceuticals Inc.’s EPS (earnings per share) are -1.5. A high EPS indicates strong profitability but may already be priced in, while a low EPS could signal weak earnings or a turnaround opportunity, requiring industry comparison.
- BioCryst Pharmaceuticals Inc.’s PE (price earnings ratio) is 7.37. A low PE ratio may suggest undervaluation but could also indicate slow growth or risk, whereas a high PE ratio reflects high growth expectations but may signal overvaluation, necessitating a check on earnings sustainability.
The below BioCryst Pharmaceuticals Inc. share price analysis and market data includes key financials, earnings estimates, peer performance, dividends, news and a company profile that will give you an indication as to whether this stock is a buy, sell or hold. Subscribe to Good Money Guide Analysis for expert opinion on the latest investment opportunities.
[qmod analyst|earnings|financials|financialsummary|pricehistory|interactivechart|dividends|corporateevents|shareinfoperformance|fullnews|companyprofile BCRX:US name=”BioCryst Pharmaceuticals Inc.” show_profile=”1″ ticker=”BCRX” heading=”h2″]



